Sanofi-Aventis' diabetes drug, Lantus, has been on the market since
2000 and achieved blockbuster status last year; analysts say despite the entrance into the market of two competing drugs, Lantus should have increasing sales over the next five years. One analyst says Lantus has done well because it is the only once-a-day long-acting analogue and that gives it an advantage over the
competition. Novo Nordisk's Levemir and Byetta, from Eli Lilly and Amylin Pharmaceuticals, were approved
earlier this year.

Full Story:

Related Summaries